Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals: China approves etripamil nasal spray for PSVT, triggers $2.0 million payment

Positive Impact 3 of 5 product/contract Written later

Milestone Pharmaceuticals announced that China's National Medical Products Administration approved etripamil nasal spray for paroxysmal supraventricular tachycardia in adults, the first approval of the drug outside the United States. The approval triggers a $2.0 million milestone payment to Milestone and makes it eligible for up to $98.0 million more in milestones and tiered royalties of up to 18% from Everest Medicines, its Greater China licensee.

Key points

  • NMPA approval announced September 3, 2026; first regulatory approval of etripamil outside the United States
  • $2.0 million milestone payment to Milestone triggered by the approval
  • Everest Medicines holds an exclusive Greater China license and will lead commercialization
  • Milestone is eligible for up to $98.0 million in commercial and development milestones and royalties up to 18%

The filing

CompanyMilestone Pharmaceuticals Inc. (MIST)
Form8-K, current report
Filed with the SECSep 3, 2026, 4:03 PM ET
Accession number0001104659-26-105052

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.